Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an expert said.
Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.
Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.
The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The FDA has approved ...
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback